NEUROTRAUMA SCIENCES LLC


Associated tags: Brain, Patient, Science, Biology, Stroke, NTS, Traumatic brain injury, TBI, Pharmaceutical industry, MBA, Harvard School of Dental Medicine, Conference, Regulatory affairs, Biostatistics, MPH, VC, Epidemiology, Imperial College London, Injury, Neuroscience, Neuron, Inflammation, Shirin David

Locations: GEORGIA, WASHINGTON, CANADA, QUEBEC, BELGIUM, US, EUROPE, UK

NeuroTrauma Sciences Announces Key Appointments to its Executive Leadership Team

Retrieved on: 
Wednesday, May 10, 2023
Harvard School of Dental Medicine, PPD, KU Leuven, Research and development, NTS, Medical Affairs Bureau, Pfizer, Senior, University of Brussels, Traumatic brain injury, Université Laval, Stroke, New product development, MBA, Thermo Fisher Scientific, CMO, Concordia University, Harvard T.H. Chan School of Public Health, CNS, DSM-IV codes, Bachelor of Science, Central nervous system, Eisai, Public health, Doctor of Science, MD, Columbia Business School, Tropical medicine, Master of Science, Bernhard Nocht Institute for Tropical Medicine, Quality assurance, Growth, Shirin David, Merck, Regulatory affairs, Biostatistics, MPH, VC, Epidemiology, Imperial College London, Injury, Management, Pharmaceutical industry, Neuroscience

Dr. de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team in his role as Chief Medical Officer.

Key Points: 
  • Dr. de Somer brings more than 30 years of leadership in the biopharmaceutical industry to the NTS management team in his role as Chief Medical Officer.
  • He held clinical development leadership responsibilities in Europe, the UK, and the US at Sandoz/Novartis Pharmaceuticals.
  • "We are pleased to welcome these industry veterans to our leadership team," said Carl Long, Chief Executive Officer.
  • We will value their leadership and direction as we advance NTS-104 through the clinic."

NeuroTrauma Sciences Presents Update on Neuroprotective Compounds NTS-104 and NTS-105 at the 12th Annual Traumatic Brain Injury Conference

Retrieved on: 
Tuesday, June 7, 2022
Science, Conference, Stroke, LLC, MBA, NTS, Neuron, Inflammation, Traumatic brain injury, Brain, Disability, DC, Patient, Trauma, Neurosteroid, Ischemia, Death, TBI, Pharmaceutical industry, Medical imaging

ATLANTA, June 7, 2022 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the devastating effects of traumatic brain injury (TBI), today provided an update on the development of its lead drug candidates NTS-104 and NTS-105 in traumatic brain injury.

Key Points: 
  • ATLANTA, June 7, 2022 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the devastating effects of traumatic brain injury (TBI), today provided an update on the development of its lead drug candidates NTS-104 and NTS-105 in traumatic brain injury.
  • Tom J. Parry, Ph.D., MBA, Chief Science Officer, presented recent results during an oral session at the 12th Annual Traumatic Brain Injury Conference held in Washington, DC.
  • NTS-105 rapidly enters the brain at concentrations sufficient to modulate key target receptors, protecting neurons from inflammation, ischemia and programmed cell death.
  • NeuroTrauma Sciences (NTS) is a biopharmaceutical company advancing its mission to address the range of deficits caused by stroke and traumatic brain injury.

NeuroTrauma Sciences Announces Expansion of Its Executive Leadership Team

Retrieved on: 
Wednesday, March 24, 2021
Chief financial officer

Ms. Hedstrom joined NeuroTrauma Sciences as Vice President of Operations shortly after its founding and is assuming the role of Chief Operating Officer, responsible for the strategic and operational leadership of the company.

Key Points: 
  • Ms. Hedstrom joined NeuroTrauma Sciences as Vice President of Operations shortly after its founding and is assuming the role of Chief Operating Officer, responsible for the strategic and operational leadership of the company.
  • She is an accomplished executive leader, with more than 25 years' experience in accelerating life science product development and growth.
  • Dr. Caggiano brings more than 20 years of leadership in the biopharmaceutical industry to the NTS management team in his role as Chief Medical Officer and Head of Research & Development.
  • Mr. Lawrence brings significant financial expertise and biotechnology-focused leadership to NeuroTrauma Sciences in his new position as Chief Financial Officer and he will assume responsibility for the oversight of NTS's financial operations.

NeurExo Sciences and Henry Ford Health System Present Preclinical Data on Exosomes at ISEV2019 Annual Meeting

Retrieved on: 
Friday, April 26, 2019
Medicine, Clinical medicine, Cancer treatments, Chemotherapy, Cancer, Chemotherapy-induced peripheral neuropathy, Exosome, Peripheral neuropathy

Among their key findings, Henry Ford researchers demonstrated the ability of exosomes to suppress chemotherapy-induced peripheral neuropathy and enhance the anti-tumor effects of platinum drugs, which are commonly used to treat cancers.

Key Points: 
  • Among their key findings, Henry Ford researchers demonstrated the ability of exosomes to suppress chemotherapy-induced peripheral neuropathy and enhance the anti-tumor effects of platinum drugs, which are commonly used to treat cancers.
  • Neurotoxicity often requires platinum drug dose reduction, compromising therapeutic efficacy of platinum drugs to suppress tumor progression.
  • Tumor bearing mice treated with platinum drugs along with CEC-exos (n=7/group) exhibited significant reduction of platinum-drug induced peripheral neuropathy.
  • "Our preclinical data demonstrate the ability of the exosome treatment to ameliorate platinum-drug induced peripheral neuropathy," said Dr. Zhang.